Yazar "Isik, Serhat" seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Antiplatelet Effect of Sequential Administration of Cilostazol in Patients with Acetylsalycilic Acid Resistance(Taiwan Soc Cardiology, 2016) Cakmak, Muzaffer; Demircelik, Bora; Cetin, Mustafa; Cetin, Zehra; Isik, Serhat; Cicekcioglu, Hulya; Ulusoy, Feridun VasfiBackground: Acetylsalicylic acid (ASA) resistance in patients with coronary artery disease is an important medical problem that can affect treatment decision-making and outcomes. Cilostazol has been investigated to determine its effectiveness in patients with acetylsalicylic acid resistance. The aim of this study was to evaluate the antiplatelet efficacy of sequential administration of CLZ in patients with ASA resistance. Methods: A total of 180 patients were enrolled in our study. Patients with stable coronary artery disease were first given orally ASA 100 for 10 days, followed by collagen/epinephrine induced closure time (CTCEPI) measurements. Those who were found to be resistant to orally 100 mg of ASA were given orally 300 mg of ASA for an additional 10 days after which we repeated CTCEPI measurements. Those patients with resistance to orally 300 mg ASA were then given CLZ at a daily dose of orally 200 mg for 10 days followed by a final CTCEPI measurement. Results: The rate of resistance to 100 mg ASA was 81/180 (45%) compared to a rate of 35/81 (43.2%) with 300 mg ASA. Of the 35 patients found to be resistant to 300 mg ASA, 22 (62.9%) also failed to respond to CLZ treatment. Overall, sequential administration of 300 mg ASA and 200 mg CLZ resulted in a reduction in the number of non-responders from 45% to 12.2%. Conclusions: Initiation of CLZ could be of benefit in some patients with ASA-resistance for whom an effective anti-aggregant effect is of clinical importance.Öğe Antiplatelet Effect of Sequential Administration of Cilostazol in Patients with Asetylsalycilic Acid Resistance(Elsevier Science Inc, 2013) Demircelik, Muhammed Bora; Cetin, Mustafa; Cetin, Zehra Guven; Isik, Serhat; Sahin, Muslum; Kiziltunc, Emrullah; Cicekcioglu, Hulya[Abstract Not Available]Öğe No Relationship between Osteocalcin and the Microvascular Complications of Type 2 Diabetes(Galenos Yayincilik, 2014) Kucukler, Ferit Kerim; Bardak, Simge; Celik, Tugrul; Tutuncu, Yasemin; Akbaba, Gulhan; Isik, Serhat; Karaahmetoglu, SelmaPurpose: Osteocalcin, one of the osteoblast-specific proteins is produced and secreted by osteoblasts. Although osteocalcin has been thought to play a role only in bone formation, recent studies have shown that it also enhances insulin sensitivity and insulin secretion from pancreatic beta cells. Several studies have reported lower serum osteocalcin levels in patients with type 2 diabetes mellitus (T2DM) than in non-diabetic individuals; and a negative correlation between microvascular complications and osteocalcin levels in type 1 diabetes mellitus (T1DM) patients. We investigated the relationship between microvascular complications and serum undercarboxylated osteocalcin (uOC) levels in T2DM patients. Material and Method: One hundred seventy-nine patients with T2DM aged between 30 and 60 years were randomly included in the study; 101 patients with microvascular complications formed the patient group, and the other 78 without a microvascular complication formed the control group. The patients were evaluated for diabetic nephropathy, retinopathy and neuropathy. The ELISA method was used to measure uOC levels. Results: The two groups were statistically similar with regard to age, gender and body mass index (BMI). Duration of diabetes was shorter in control group than in patient group (p<0.05). HbA1c level in patient group was significantly higher than in controls (p<0.05). There was no statistically significant difference in uOC levels between the groups (p>0.05). Discussion: There was no relationship between serum osteocalcin levels and the microvascular complications of T2DM.
